Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Tackle Tricky Lung Complications in Connective Tissue Disease

Susan Bernstein  |  February 15, 2013

Treatment decisions may be complicated further by comorbidities like pulmonary hypertension, a condition that can lead to heart failure, said Stephen Mathai, MD, assistant professor of medicine at the Johns Hopkins University School of Medicine in Baltimore. Pulmonary hypertension commonly complicates connective tissue–associated ILD, he said. The condition is related to multiple etiologies and must be assessed and treated on a case-by-case basis.

Incidence of pulmonary hypertension in ILD is difficult to assess, but some tests provide clues. Systemic sclerosis-ILD-PH is defined with a right ventricular systolic pressure (RVSP) measurement greater than 35 mm Hg. In patients with RA-ILD-PH, the RVSP is greater than 30 mm Hg. In both sets of patients, it is important to look at both pulmonary function and imaging results, Dr. Mathai said. However, an estimate of RVSP is only possible in 54% of patients with ILD, he added. Other tests to help diagnose pulmonary hypertension include echocardiogram, diffusing capacity (DLCO), and FVC/DLCO.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Pulmonary hypertension is a bad prognostic indicator in many pulmonary conditions, and ILD is no exception,” said Dr. Mathai. Comorbidities need to be addressed in these patients, including heart failure with preserved ejection fraction, pulmonary embolism, and coronary artery disease, which is common. Obstructive sleep apnea may be seen, prompting treatment with an end-tidal or transcutaneous carbon dioxide monitor. Atrial arrhythmias are very poorly tolerated in pulmonary hypertension patients, he said.

Goals of treatment include improving functional capacity and quality of life as well as survival, Dr. Mathai said. If there is a reduction of oxygen content in the alveoli, constriction may lead to a worsening of oxygenation, he added. Current therapies include vasodilators, including oxygen therapy for patients with chronic hypoxemia; diuretics for patients with volume overload; and digoxin for patients who need to increase cardiac output.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Susan Bernstein is a freelance medical journalist based in Atlanta.

 

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:connective tissue diseaseInterstitial Lung DiseaseSystemic sclerosis

Related Articles

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients

    February 15, 2017

    SAN FRANCISCO—Interstitial lung disease (ILD) represents a heterogeneous group of disorders characterized by inflammation or fibrosis of the lungs. The disorders are also associated with a spectrum of connective tissue diseases (CTDs). ILD is a common manifestation of CTDs, such as scleroderma, poly-/dermatomyositis and rheumatoid arthritis—and is a leading cause of morbidity and mortality in…

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    Labored Breathing

    January 1, 2007

    Strategies to diagnose and manage dyspnea in the scleroderma patient

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences